J. Miceli

发表

Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment

K. Rickels, T. Shiovitz, T. Ramey, 2012, International clinical psychopharmacology.

Ziprasidone Metabolism, Aldehyde Oxidase, and Clinical Implications

R. Obach, C. Beedham, J. Miceli, 2003, Journal of clinical psychopharmacology.

Electrocardiographic changes with ziprasidone.

P. Chappell, A. Loebel, C. Siu, 2006, Journal of the American Academy of Child and Adolescent Psychiatry.

Single-dose pharmacokinetics and safety of ziprasidone in children and adolescents.

T. Tensfeldt, K. Wilner, F. Sallee, 2006, Journal of the American Academy of Child and Adolescent Psychiatry.

Ziprasidone and the Corrected QT Interval

T. Tensfeldt, A. Camm, J. Kane, 2012, CNS Drugs.

Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers.

K. Wilner, R. Hansen, G. Apseloff, 2000, British journal of clinical pharmacology.

The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers.

R. Anziano, R. Hansen, J. Miceli, 2000, British journal of clinical pharmacology.

Renal response to furosemide in very low birth weight infants during chronic administration.

M. Mirochnick, J. Miceli, J. Raye, 1990, Developmental pharmacology and therapeutics.

Furosemide pharmacokinetics in very low birth weight infants.

M. Mirochnick, J. Miceli, J. Raye, 1988, The Journal of pediatrics.

The Effect of Timing of a Standard Meal on the Pharmacokinetics and Pharmacodynamics of the Novel Atypical Antipsychotic Agent Ziprasidone

K. Wilner, M. Lebel, J. Miceli, 1998, Pharmacotherapy.

A Randomized Evaluation of the Effects of Six Antipsychotic Agents on QTc, In the Absence and Presence of Metabolic Inhibition

R. Anziano, N. Cutler, T. Shiovitz, 2004, Journal of clinical psychopharmacology.

Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions.

D. Tweedie, C. Prakash, C Prakash, 2000, British journal of clinical pharmacology.

Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteers.

K. Wilner, C. Prakash, J. Miceli, 1998, Drug metabolism and disposition: the biological fate of chemicals.

Pharmacodynamics of ziprasidone in children and adolescents: impact on dopamine transmission.

K. Wilner, D. Gilbert, F. Sallee, 2003, Journal of the American Academy of Child and Adolescent Psychiatry.

Comparison of pregabalin with pramipexole for restless legs syndrome.

J. Winkelman, R. Allen, D. Garcia-Borreguero, 2014, The New England journal of medicine.

Bioavailability Studies of Drugs with Nonlinear Pharmacokinetics: II. Absolute Bioavailability of Intravenous Phenytoin Prodrug at Therapeutic Phenytoin Serum Concentrations Determined by Double‐Stable Isotope Technique

T. Browne, G. Szabo, J. Evans, 1993, Journal of clinical pharmacology.

Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder.

M. Versavel, M. DelBello, J. Miceli, 2008, Journal of child and adolescent psychopharmacology.

A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer’s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil

T. Fullerton, M. Delnomdedieu, J. Mancuso, 2018, Alzheimer's Research & Therapy.

A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome.

Barry T. Peterson, R. Allen, D. Garcia-Borreguero, 2009, Sleep medicine.

Effects of Oral Ziprasidone and Oral Haloperidol on QTc Interval in Patients with Schizophrenia or Schizoaffective Disorder

R. Anziano, T. Tensfeldt, T. Shiovitz, 2010, Pharmacotherapy.

Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study

E. Vieta, A. Loebel, T. Ramey, 2010, Journal of Psychopharmacology.

The effect of food on the absorption of oral ziprasidone.

K. Wilner, P. Glue, J. Alderman, 2007, Psychopharmacology bulletin.

Pharmacokinetics, Safety, and Tolerability of Intramuscular Ziprasidone in Healthy Volunteers

T. Tensfeldt, K. Wilner, S. Swan, 2005, Journal of clinical pharmacology.

Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.

R. Anziano, T. Tensfeldt, T. Shiovitz, 2010, Clinical therapeutics.

The Anxiolytic Effect of the Novel Antipsychotic Ziprasidone Compared With Diazepam in Subjects Anxious Before Dental Surgery

R. Anziano, K. Wilner, A. Johnson, 2002, Journal of clinical psychopharmacology.

The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers.

J. Miceli, A. Laurent, L. Robarge, 2000, British journal of clinical pharmacology.

Pregabalin versus pramipexole: effects on sleep disturbance in restless legs syndrome.

R. Allen, D. Garcia-Borreguero, S. Dubrava, 2014, Sleep.

FUROSEMIDE PHARMACODYNAMICS FOLLOWING ACUTE & CHRONIC ADMINISTRATION

M. Mirochnick, J. Miceli, J. Raye, 1987, Pediatric Research.

The pharmacokinetics of CP-88,059 in healthy male volunteers following oral and intravenous administration

K. Wilner, J. Miceli, T. Hunt, 1994 .

A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer’s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil

T. Fullerton, M. Delnomdedieu, J. Mancuso, 2016, Alzheimer's Research & Therapy.

P-10-37 Anxiolytic effects of ziprasidone compared with diazepam and placebo prior to dental surgery

R. Anziano, K. Wilner, A. Johnson, 1996, European Neuropsychopharmacology.